Partnership between Sonrai and AOA Dx aims to expedite the creation of a diagnostic test for ovarian cancer
Headline: Sonrai Analytics and AOA Dx Partner to Advance Ovarian Cancer Diagnostic Test
Sonrai Analytics and AOA Dx, two pioneering companies in their respective fields, have formed a strategic partnership to develop a diagnostic test for ovarian cancer in symptomatic women. The collaboration involves a multi-omic biomarker validation strategy, which aims to improve the accuracy and effectiveness of the test [1].
AOA Dx, an early-stage biotech company, is at the forefront of developing this diagnostic, while Sonrai Analytics brings expertise in data analysis for biomarker validation. The Sonrai Discovery platform will enable AOA to store and manage their clinical data in a controlled environment, facilitating cross-functional collaboration and real-time performance tracking.
Sonrai will offer its bioinformatics expertise, enabling AOA to harness pre-built machine learning tools and run automated pipelines. This will support AOA in validating diagnostic biomarkers, enhancing the accuracy and clinical utility of its serum-based test for ovarian cancer.
Dr Abigail McElhinny, Chief Scientific Officer of AOA Dx, stated that the partnership will allow AOA to integrate and manage their in-house development data, cross-reference it with public datasets, and analyze it seamlessly within one centralized environment.
Meanwhile, in the field of breast imaging, b-rayZ has been designated as Affidea's AI Partner. This partnership is aimed at improving breast imaging technology.
In the realm of neuroscience, Aptamer Group and Neuro-Bio are advancing a new Alzheimer's diagnostic test. The new test uses advanced diagnostic methods and leverages a combination of novel gangliosides, lipids, and proteins to diagnose Alzheimer's disease in patients. However, it is still under development.
PathAI has received FDA clearance for its AISight Dx platform, which was granted on a 510(k) basis. The platform received clearance for the detection and diagnosis of various cancers.
These collaborations and advancements in diagnostic technology are significant steps towards early and more accurate detection of diseases like ovarian cancer and Alzheimer's disease, potentially saving lives and improving the quality of life for many individuals.
[1] Sonrai Analytics and AOA Dx Announce Strategic Partnership to Accelerate Development of AOA’s Multi-omic Liquid Biopsy Test for Ovarian Cancer. (2021, May 19). PR Newswire. Retrieved August 1, 2021, from https://www.prnewswire.com/news-releases/sonrai-analytics-and-aoa-dx-announce-strategic-partnership-to-accelerate-development-of-aoas-multi-omic-liquid-biopsy-test-for-ovarian-cancer-301302959.html
- This partnership between Sonrai Analytics and AOA Dx focuses on digital health, combining their expertise to develop a diagnostic test for ovarian cancer [1].
- The partnership utilizes a multi-omic biomarker validation strategy, which is a key aspect of the field of science and medical-conditions, to improve diagnostic test accuracy and effectiveness.
- With Sonrai Analytics' bioinformatics expertise, AOA Dx will utilize artificial intelligence in analyzing clinical data, enabling the validation of diagnostic biomarkers for cancer [1].
- Meanwhile, in the health-and-wellness sector, advancements in technology are also being made, like the collaboration between b-rayZ and Affidea to improve breast imaging technology.
